Gandeeva Therapeutics, a Vancouver, BC, Canada-based precision biotechnology company harnessing the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop novel therapeutics at an accelerated pace, raised US$40m in Series A funding.
The round was led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures, Amplitude Ventures and Air Street Capital.
The company intends to use the funds to advance its AI-driven cryo-EM platform with the aim to accelerate the discovery, design and development of novel precision medicines.
Led by Dr. Sriram Subramaniam, Founder and CEO, Gandeeva Therapeutics has developed a proprietary platform that combines innovative technologies across biochemistry, structural biology, imaging and machine learning to characterize protein-drug interactions at the atomic level, all designed to provide new insights into targeting protein function.
FinSMEs
31/01/2022